Open Access iconOpen Access

ARTICLE

Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

Xiuhua Weng*1, Shaohong Luo*1, Shen Lin*, Lixian Zhong, Meiyue Li*, Rao Xin*, Pinfang Huang*, Xiongwei Xu*

* Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Taijiang, Fuzhou, P.R. China
† College of Pharmacy, Texas A&M University, College Station, TX, USA

TSP_OR_96504019.pdf

  • 608

    View

  • 382

    Download

  • 0

    Like

Share Link